Signal price

Masimo (NASDAQ:MASI) Price target raised to $179.00


Masimo (NASDAQ:MASI – Get a Rating) had its price target raised by stock analysts Needham & Company LLC from $163.00 to $179.00 in a report on Wednesday, Stock Target Advisor reports. The company currently has a “buy” rating on shares of the medical equipment supplier. Needham & Company LLC’s target price would indicate a potential upside of 16.83% from the company’s previous close.

MASI has been the subject of several other research reports. Stifel Nicolaus cut his price target on Masimo shares from $175.00 to $150.00 in a Wednesday May 4 research note. Piper Sandler raised her price target on Masimo shares from $130.00 to $135.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, StockNews.com upgraded Masimo shares from a “hold” rating to a “buy” rating in a Wednesday, July 13 research note. Four analysts gave the stock a hold rating and three gave the company a buy rating. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $183.80.

Masimo shares down 2.9%

The NASDAQ MASI opened Wednesday at $153.21. The company has a market capitalization of $8.50 billion, a PE ratio of 46.15 and a beta of 0.98. The company has a 50-day moving average price of $137.50 and a 200-day moving average price of $148.88. Masimo has a 52-week low of $112.07 and a 52-week high of $305.21.

Masimo (NASDAQ:MASI – Get Rating) last released its quarterly earnings data on Tuesday, August 9. The medical equipment supplier reported EPS of $1.35 for the quarter, beating the consensus estimate of $1.19 by $0.16. The company posted revenue of $565.30 million in the quarter, compared to analyst estimates of $540.56 million. Masimo had a net margin of 12.68% and a return on equity of 16.45%. Masimo’s revenue increased 87.9% year over year. In the same quarter a year earlier, the company posted EPS of $0.94. On average, stock research analysts expect Masimo to post earnings per share of 4.61 for the current fiscal year.

Masimo Institutional Trading

Major investors have recently changed their positions in the company. Comerica Bank increased its stake in Masimo shares by 3.4% in the 1st quarter. Comerica Bank now owns 23,749 shares of the medical equipment supplier valued at $3,235,000 after acquiring 786 additional shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in Masimo during the first quarter worth $213,000. Itau Unibanco Holding SA acquired a new stake in Masimo during the fourth quarter at a value of $80,000. Shell Asset Management Co. increased its stake in Masimo by 69.7% in the first quarter. Shell Asset Management Co. now owns 54,404 shares of the medical equipment supplier worth $7,918,000 after buying an additional 22,345 shares last quarter. Finally, Veriti Management LLC purchased a new stake in Masimo during the first quarter at a value of $265,000. 92.03% of the shares are held by hedge funds and other institutional investors.

Masimo Company Profile

(Get an assessment)

Masimo Corporation develops, manufactures and markets noninvasive monitoring technologies and hospital automation solutions worldwide. Company offers pulse oximetry based on Masimo Signal Extraction Technology (SET) with measurement through motion and low perfusion pulse oximetry monitoring to address key limitations of conventional pulse oximetry .

Featured articles

Stock Target Advisor Logo

Analyst Recommendations for Masimo (NASDAQ: MASI)



Get news and reviews for Masimo Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Masimo and related companies with MarketBeat.com’s free daily email newsletter.